Cargando…

Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice

INTRODUCTION: In clinical trials, toxicity leading to discontinuation of tenofovir (TDF) is a rare occurrence (3% by two years)[1, 2]; however, in clinical practice it seems to be higher. Previous studies suggested that TDF toxicity is higher when it is co-administered with ritonavir-boosted proteas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Costarelli, Silvia, Cozzi-Lepri, Alessandro, Lapadula, Giuseppe, Bonora, Stefano, Madeddu, Giordano, Maggiolo, Franco, Antinori, Andrea, Gori, Andrea, D'Arminio-Monforte, Antonella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Poster Sessions – Abstract P039
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224916/ https://www.ncbi.nlm.nih.gov/pubmed/25394078 http://dx.doi.org/10.7448/IAS.17.4.19571

Ejemplares similares

Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice
por: Costarelli, Silvia, et al.
Publicado: (2016)

Durability of lopinavir/ritonavir dual-therapies in individuals with viral load <50 copies/mL in the observational setting
por: Gianotti, Nicola, et al.
Publicado: (2014)

Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy
por: Cozzi-Lepri, Alessandro, et al.
Publicado: (2014)

Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort
por: Di Biagio, Antonio, et al.
Publicado: (2014)

An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy
por: Cozzi-Lepri, Alessandro, et al.
Publicado: (2014)

Increased incidence of sexually transmitted diseases in the recent years: data from the ICONA cohort
por: Cingolani, Antonella, et al.
Publicado: (2014)

Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort
por: d’Arminio Monforte, Antonella, et al.
Publicado: (2016)

Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study
por: Spagnuolo, Vincenzo, et al.
Publicado: (2014)

Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy
por: Bandera, Alessandra, et al.
Publicado: (2015)

Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus
por: Mussini, Cristina, et al.
Publicado: (2015)

Time spent with HIV-RNA ≤ 200 copies/ml in a cohort of people with HIV during the U=U era
por: Madeddu, Giordano, et al.
Publicado: (2021)

Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients
por: Gianotti, Nicola, et al.
Publicado: (2017)

Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy
por: Di Biagio, Antonio, et al.
Publicado: (2016)

AVALIAÇÃO DOS CASOS DE EMBOLIA PULMONAR ASSOCIADA AO COVID 19 EM HOSPITAL PRIVADO DO INTERIOR DO ESTADO DE SÃO PAULO
por: Morejón, Karen Mirna Loro, et al.
Publicado: (2021)

Le traitement par rituximab diminue la réponse humorale, mais pas la réponse cellulaire, après vaccination anti-SARS-CoV-2 chez des patients atteints de maladie auto-immune
por: Bitoun, S., et al.
Publicado: (2021)

INFECÇÃO POR SARS-COV-2 EM VOLUNTÁRIOS DO ENSAIO CLÍNICO DA VACINA CHADOX1 NCOV-19
por: Barbosa, Gabriela, et al.
Publicado: (2022)

A LETALIDADE EM HOSPITAIS DO PARANÁ NOS INTERNAMENTOS POR COVID-19
por: Klosowski, Luiz Augusto, et al.
Publicado: (2022)

IMPACTO DA PANDEMIA DE COVID-19 NO DESFECHO DE TRATAMENTO DA TUBERCULOSE EM HOSPITAL TERCIÁRIO
por: Garcia, Marcia Teixeira, et al.
Publicado: (2022)

SECONDARY URTICARIAL VASCULITIS AND CHRONIC SPONTANEOUS URTICARIA ASSOCIATED WITH COVID-19 VACCINATION
por: Chang, T., et al.
Publicado: (2022)

Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort
por: Pinnetti, Carmela, et al.
Publicado: (2014)

High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects: Data from the ICONA Foundation Cohort
por: Squillace, Nicola, et al.
Publicado: (2016)

Lamivudine plus darunavir boosted with ritonavir as simplification dual regimen in HIV-infected patients
por: Luis Casado, Jose, et al.
Publicado: (2014)

Potential implications of CYP3A4, CYP3A5 and MDR-1 genetic variants on the efficacy of Lopinavir/Ritonavir (LPV/r) monotherapy in HIV-1 patients
por: Berno, Giulia, et al.
Publicado: (2014)

CD4 cell count and the risk of infective and non-infective serious non-AIDS events in HIV-positive persons seen for care in Italy
por: Madeddu, Giordano, et al.
Publicado: (2014)

Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial
por: Fabbiani, Massimiliano, et al.
Publicado: (2014)

Viro-immunological characterization of naïve patients with high cerebrospinal fluid (CSF) HIV RNA
por: Iannuzzi, Francesca, et al.
Publicado: (2014)

Effectiveness of dolutegravir‐based regimens as either first‐line or switch antiretroviral therapy: data from the Icona cohort
por: Mondi, Annalisa, et al.
Publicado: (2019)

Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study
por: Mussini, Cristina, et al.
Publicado: (2018)

Effectiveness and durability of darunavir/ritonavir (DRV/r) in DRV/r-experienced HIV-1-infected patients in routine clinical practice
por: Antinori, Andrea, et al.
Publicado: (2014)

Factors associated with HPV-DNA clearance in a cohort of HIV-positive patients: role of cART and gender
por: Suardi, Elisa, et al.
Publicado: (2014)

Determinants of loss to care and risk of clinical progression in PLWH who are re-engaged in care after a temporary loss
por: Mussini, Cristina, et al.
Publicado: (2021)

Switching to nevirapine-based regimens after undetectable viral load is not associated with increased risk of discontinuation due to toxicity
por: Patterson, Patricia, et al.
Publicado: (2014)

Reply to Manfredi
por: Lichtner, Miriam, et al.
Publicado: (2015)

Safety of darunavir/ritonavir (DRV/r) in HIV-1-infected DRV/r-experienced and -naïve patients: analysis of data in the real-world setting in Italy
por: Antinori, Andrea, et al.
Publicado: (2014)

Mise à jour des recommandations EULAR sur l’utilisation des thérapies immunomodulatrices dans la prise en charge de la Covid-19
por: Najm, A., et al.
Publicado: (2021)

Association between abdominal aortic calcifications, bone mineral density and vertebral fractures in a cohort of HIV-positive patients
por: Iannotti, Nathalie, et al.
Publicado: (2014)

Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor–Based Regimen: The “STORE” Study
por: Gori, Andrea, et al.
Publicado: (2020)

Reduced HIV symptoms and improved health-related quality of life correlate with better access to care for HIV-1 infected women: the ELLA study
por: Baran, Robert, et al.
Publicado: (2014)

Randomized trial of DRV/r or LPV/r QD monotherapy vs maintaining a PI/r-based antiretroviral regimen in persons with suppressed HIV replication
por: Pinnetti, Carmela, et al.
Publicado: (2014)

Increased risk of virological failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort
por: Saracino, Annalisa, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_7tcjmngm8k3jgvbuoooqegieav